PROCEPT BioRobotics Q3 2026 earnings

PRCT · 2026-11-04 16:18 AMC ET · 8-K on SEC

Revenue growth of 18% to $98.3 million, gross margin stable at 66%, and continued investment in R&D and sales.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$98.3M+18%+4.1%Ex. 99.1, income statement
EPS (GAAP)-$0.46+8.6%+2.1%Ex. 99.1, income statement
EPS (adjusted)-$0.27+8.4%+2.3%Ex. 99.1, income statement
Net income-$26.5M+23.8%+0.9%Ex. 99.1, income statement
Adj. EBITDA-$9.8M+32.3%+13.3%Ex. 99.1, income statement
Adj. EBITDA margin-10.0%+2.5 pp+1.7 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
U.S.$85.8M+16%87%System revenue flat YoY
International$12.5M+32%13%Strongest growth driver

Margins and costs

  • Gross margin 66% (prior 65%, change +1.0 pp)
  • Operating expenses $92.5M (+19.3% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 0.2% (prior-year -0.2%, year-to-date -0.0%)
  • Non-GAAP bridge Adds back depreciation, amortization, and stock-based compensation

KPIs

MetricActualPrior quarterPrior yearChange
U.S. procedures13,400+13,100+11,000++22% YoY, +2.3% QoQ
U.S. HYDROS systems6265N/A20 replacement systems
Handpiece ASP$3,570$3,550$3,200+12% YoY, +0.6% QoQ
Cash & equivalents$218.4M$227.9MN/A-4.2% QoQ

Guidance

MetricGuidePrior guideChange
Revenue$390M - $410M$390M - $410MReiterated
U.S. procedure volume54,000 - 56,00054,000 - 56,000Reiterated
Gross marginApprox. 65%Approx. 65%Reiterated
Adjusted EBITDA loss$35M - $30M$35M - $30MReiterated

What drove it

  • Revenue story U.S. revenue grew 16% to $85.8M; international revenue grew 32% to $12.5M.
  • EPS story EPS improvement driven by revenue growth and improved adjusted EBITDA margin.
  • One-off check None stated

The good

  • U.S. procedure volume growth of 22%
  • International revenue growth of 32%
  • Gross margin of 66%

The bad

  • Net loss of $26.5M
  • Adjusted EBITDA loss of $9.8M
  • Operating expenses increased 19.3% YoY

The ugly

  • none

Open questions

  • The release does not disclose the prior quarter's revenue or EPS for comparison.
  • The release does not disclose the prior quarter's Adjusted EBITDA or margin for comparison.
Full release

PROCEPT BioRobotics (PRCT) earnings release, November 4, 2026

PROCEPT BioRobotics Corp (PRCT) · Form 8-K, Item 2.02 · Filed · SEC filing

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

SAN JOSE, Calif., November 4, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.

“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan,” said Larry Wood, Chief Executive Officer. “Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”

Wood continued, “This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”

Third Quarter 2026 Financial Results

• Total revenue of $98.3 million for the third quarter of 2026, an increase of 18% compared to the prior year period in 2025

• U.S. procedures over 13,400 for the third quarter of 2026, an increase of approximately 22% compared to the prior year period

• Delivered 62 U.S. HYDROS systems, which included 20 replacement systems. U.S. average selling price was approximately $495,000 for new HYDROS systems

• U.S. handpieces sold as percent of U.S. procedures in the third quarter of 2026 was approximately 106%

• Third quarter of 2026 handpiece average selling price of approximately $3,570 increased 12% compared to the third quarter of 2025

• International revenue of $12.5 million for the third quarter of 2026, an increase of 32% compared to the prior year period

• Gross margin of 66% for the third quarter of 2026, compared to 65% in the prior year period.

Total revenue for the third quarter of 2026 was $98.3 million, an increase of 18% compared to the prior year period. The increase was driven by increased U.S. handpiece and system revenue and international revenue. U.S. revenue was $85.8 million, representing growth of 16% compared to the prior year period. U.S. handpiece and consumable revenue for the third quarter of 2026 was $53.9 million, an increase of 21% compared to the prior year period. U.S. system revenue for the third quarter of 2026 was $24.7 million, flat compared to the prior year period. International revenue was $12.5 million for the quarter, an increase of 32% compared to the prior year period.

Gross margin for the third quarter of 2026 was 66% compared to 65% in the prior year period.

Operating expenses in the third quarter of 2026 were $92.5 million, compared with $77.2 million in the prior year period. The increase in operating expenses reflects continued investment in our people, product development, clinical studies and sales and marketing programs.

Net loss was $26.5 million for the third quarter of 2026, compared to a loss of $21.4 million in the prior year period. Adjusted EBITDA* was a loss of $9.8 million for the third quarter of 2026, compared to a loss of $7.4 million in the prior year period.

Cash, cash equivalents and restricted cash balances as of September 30, 2026, totaled approximately $221.4 million.

Full Year 2026 Financial Guidance

• The Company reiterates revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period

• The Company reiterates U.S. procedure volume for the full year 2026 to be in the range of 54,000-56,000 which represents growth of 25% to 29% compared to the prior year period

• The Company reiterates gross margin for the full year 2026 to be approximately 65%

• The Company reiterates adjusted EBITDA* loss for the full year 2026 to be in the range of $35 million to $30 million

*Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).

Webcast and Conference Call Information

PROCEPT BioRobotics will host a conference call to discuss the third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the links below:

• Webcast link for interested listeners:

◦ https://edge.media-server.com/mmc/p/rdtftqik/

• Dial-in registration for sell-side research analysts:

◦ https://register-conf.media-server.com/register/BIac4b002880274c7086f519f21b93cd1f

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Use of Non-GAAP Financial Measures

(Unaudited)... (truncated)he United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.

The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited, in thousands, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue98,29183,327275,922231,671
Cost of sales33,14329,32194,44781,758
Gross profit65,14854,006181,475149,913
Operating expenses:
Research and development20,01118,18761,57852,221
Selling, general and administrative72,51359,011207,269170,510
Total operating expenses92,52477,198268,847222,731
Loss from operations-27,376-23,192-87,372-72,818
Interest expense-856-919-2,516-2,692
Interest and other income, net1,6582,7344,8669,905
Loss before income taxes-26,574-21,377-85,022-65,605
Provision for (benefit from) income taxes-5834-7122
Net loss-26,516-21,411-85,015-65,727
Net loss per share, basic and diluted-0.46-0.38-1.49-1.19
Compute net loss per share attributable to
Common shareholders, basic and diluted57,32655,72756,97155,366

Income Statement

Three Months Ended September 30, — (Unaudited, in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net loss-26,516-21,411-85,015-65,727
Depreciation and amortization expense2,5391,6196,2644,681
Stock-based compensation expense15,08014,49042,68636,761
Interest (income) and interest expense, net-925-2,093-3,209-6,913
Adjusted EBITDA-9,822-7,395-39,274-31,198

Income Statement

For the Year Ending December 31, 2026 — (Unaudited, in thousands)

For the Year Ending December 31, 2026 – LOWFor the Year Ending December 31, 2026 – HIGH
Net loss-97,800-92,800
Depreciation and amortization expense8,8008,800
Stock-based compensation expense58,20058,200
Interest (income) and interest expense, net-4,200-4,200
Adjusted EBITDA-35,000-30,000

Income Statement

Three Months Ended September 30, — (Unaudited, in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
U.S.
System sales and rentals24,68924,74777,14165,400
Handpieces and other consumables53,86144,411145,247125,668
Service7,2754,75418,87512,723
Total U.S. revenue85,82573,912241,263203,791
Outside of U.S.
System sales and rentals4,5033,39111,75610,179
Handpieces and other consumables6,9745,31620,17515,805
Service9897082,7281,896
Total outside of U.S. revenue12,4669,41534,65927,880
Total revenue98,29183,327275,922231,671

Balance Sheet

September 30, 2026 — (Unaudited, in thousands)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents218,369286,503
Accounts receivable, net105,03083,533
Inventory81,41070,694
Prepaid expenses and other current assets9,3819,648
Total current assets414,190450,378
Restricted cash, non-current3,0383,038
Property and equipment, net30,16530,399
Operating lease right-of-use assets, net16,37317,538
Intangible assets, net502709
Other assets9,4916,019
Total assets473,759508,081
Current liabilities:
Accounts payable16,72117,285
Accrued compensation25,97623,175
Deferred revenue15,63613,048
Operating leases, current2,6552,214
Other current liabilities9,36510,073
Total current liabilities70,35365,795
Long-term debt51,76751,615
Operating leases, non-current22,57024,654
Other non-current liabilities161147
Total liabilities144,851142,211
Stockholders’ equity:
Additional paid-in capital1,055,4751,007,390
Accumulated other comprehensive gain537
Accumulated deficit-726,572-641,557
Total stockholders’ equity328,908365,870
Total liabilities and stockholders’ equity473,759508,081

This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2026, statements regarding the potential utilities, values, benefits and advantages of Aquablation therapy performed using PROCEPT BioRobotics’ products, including AquaBeam or Hydros Robotic Systems, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on the Company’s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware.

Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, procedure growth, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 26, 2026, and subsequent quarterly reports on Form 10-Q. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.

Important Safety Information

All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Media Contact: Pooja Rao, media@procept-biorobotics.com

Investor Contact: Marissa Bych, ir@procept-biorobotics.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.